15 October 2015 - Belatacept (Nulojix) has been approved since June 2011 for use by adults after a kidney transplant. Together with other medicines, it is designed to prevent the rejection of an allograft. After an initial early benefit assessment in April 2012, the Institute for Quality and Efficiency in Health Care (has IQWiG) has re-examined whether belatacept, when compared with an appropriate therapy (cyclosporin), offers an additional benefit. This was due to a limitation of a decision by the Federal Joint Committee (G-BA) that expired in July 2015.

From the second dossier, an indication of a considerable added benefit can be derived. The evidence in the first dossier supported a finding of an indication of a low added benefit.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/belatacept-nach-nierentransplantation-hinweis-auf-betrachtlichen-zusatznutzen.6927.html?&et_cid=4&et_lid=%25208 [German]